DiaMedica Therapeutics Advances Trials and Financial Position
Company Announcements

DiaMedica Therapeutics Advances Trials and Financial Position

Diamedica Therapeutics ( (DMAC) ) just unveiled an update.

DiaMedica Therapeutics announced updates to its ReMEDy2 trial for acute ischemic stroke, including expanding the patient pool and increasing interim analysis size, aimed at enhancing trial success and reducing costs. The company also reported regulatory approval for a Phase 2 trial of DM199 for preeclampsia in South Africa. Financially, DiaMedica has $50.2 million in cash and investments, with increased R&D expenses reflecting ongoing trial expansions.

Learn more about DMAC stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyDiaMedica Therapeutics reports Q3 EPS (15c), consensus (15c)
TheFlyDiaMedica Therapeutics doses first patient in Phase 2 DM199 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App